Table 1. Patients’ characteristics by dose levels.
| Characteristics | Dasatinib Dose Level (mg) | ||
|---|---|---|---|
| Dose Level 1 100 (n = 6) |
Dose Level 2 140 (n= 4) |
All patients (n= 10) |
|
| Age, years (median; range) | 44 (35-81) | 49 (47-73) | 48 (35- 81) |
| Race, n (%) | |||
| Caucasian | 5 (83) | 4 (100) | 9 (90) |
| Hispanic | 1 (17) | 0 (0) | 1 (10) |
| ECOG PS, n (%) | |||
| 0 | 2 (33) | 3 (75) | 5 (50) |
| 1 | 4 (67) | 1 (25) | 5 (50) |
| Menopausal status, n (%) | |||
| Premenopausal | 4 (67) | 1 (25) | 5 (50) |
| Postmenopausal | 2 (33) | 3 (75) | 5 (50) |
| Hormone receptors, n (%) | |||
| ER+ / PgR+ | 4 (67) | 1 (25) | 5 (50) |
| ER+ / PgR- | 1 (17) | 1 (25) | 2 (20) |
| ER- / PgR- | 1 (16) | 2 (50) | 3 (30) |
| Previous trastuzumab treatment | |||
| Yes | 2 (33) | 2 (50) | 4 (40) |
| No | 4 (67) | 2 (50) | 6 (60) |
| Previous hormonotherapy treatment | |||
| Yes | 4 (67) | 1 (25) | 5 (50) |
| No | 2 (33) | 3 (75) | 5 (50) |
| Previous radiotherapy treatment | |||
| Yes | 1 (17) | 2 (50) | 3 (30) |
| No | 5 (83) | 2(50) | 7 (70) |
| Other previous chemotherapy or biological treatment | |||
| Yes | 2 (33) | 2 (50) | 4 (40) |
| No | 4 (67) | 2 (50) | 6 (60) |
mg: milligram; n: number of patients; ECOG: Eastern Cooperative Oncology Group; PS: performance status; ER: estrogen receptor; PgR: progesterone receptor.